<DOC>
	<DOCNO>NCT02363621</DOCNO>
	<brief_summary>This study design compare post injection inflammation pain see intravitreal injection ranibizumab 0.3mg aflibercept 2.0mg patient DME . The investigator evaluate patient ( 1-7 day ) post injection : 1 . Intraocular inflammation ( define anterior chamber and/or vitreous cell 2 . Pain ( measure standardize pain scale ) .</brief_summary>
	<brief_title>Evaluation Inflammation Pain Post Injection Ranibizumab vs. Aflibercept Patients With Diabetic Macular Edema</brief_title>
	<detailed_description>This open-label , Phase II study post injection pain inflammation intravitreally administer ranibizumab aflibercept 100 subject Diabetic Macular Edema . Treatment na√Øve experience patient enrol . Treatment experience patient history anti-vegf injection eligible long received intravitreal injection 3 month prior study visit . Patients randomize receive either Lucentis 0.3 mg Eylea 2.0 mg , follow week . A non-injecting masked physician blind treatment drug evaluate patient baseline injection within 1-2 day 5-7 day injection anterior chamber vitreous cell use slit lamp examination indirect ophthalmoscopy . Pain also record visit use standardized pain scale . Consented , enrolled subject receive open-label intravitreal injection either 0.3 mg ranibizumab 2.0 mg aflibercept . A standard intravitreal injection protocol follow . Patients revaluated baseline , 1-2 day 5-7 day post injection . A non-injecting physician evaluate patient anterior chamber vitreous inflammation ; physician blind specific treatment . Anterior chamber inflammation describe cell flare anterior chamber . These evaluate use Standardization Uveitis Nomenculature ( SUN ) work group classification . Pain score evaluate use Numerical Rating Scale .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 21 year Exam OCT confirm Diabetic Macular Edema Visual Acuity 20/400 good No history post injection pain inflammation past Subjects meet follow criterion exclude study History Endophthalmitis either eye Current inflammation either eye Uncontrolled symptomatic Dry Eye Syndrome Intravitreal injection le 3 month ago History Anterior Posterior Uveitis History post injection pain prior treatment Recent thromboembolic event ( &lt; 3 month ) Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>